NCT06124417 is a Phase 4 clinical trial of Sertraline in Efficacy, Team, sponsored by First Affiliated Hospital of Chongqing Medical University.

Who is sponsoring NCT06124417?

NCT06124417 is sponsored by First Affiliated Hospital of Chongqing Medical University.

What drugs are being tested in NCT06124417?

Interventions in NCT06124417: Sertraline.

What condition does NCT06124417 study?

NCT06124417 studies Efficacy, Team, Adverse Reaction to Drug.

Is NCT06124417 still recruiting?

NCT06124417 is currently completed. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT06124417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression

Completed Phase 4 Last updated 9 November 2023

What this trial tests

Phase 4 trial testing Sertraline in Efficacy, Team in 125 participants. Completed in 29 September 2023.

Timeline

10 January 2022

Primary endpoint
25 August 2023

29 September 2023

Quick facts

Lead sponsor	First Affiliated Hospital of Chongqing Medical University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	125
Start date	10 January 2022
Primary completion	25 August 2023
Estimated completion	29 September 2023
Sites	1 location across China

Drugs / interventions tested

Sertraline (sertraline) — full drug profile →

Conditions studied

Efficacy, Team — all drugs for Efficacy, Team →
Adverse Reaction to Drug — all drugs for Adverse Reaction to Drug →

Sponsor

First Affiliated Hospital of Chongqing Medical University

Who can join

Adults 18 to 90, any sex, with Efficacy, Team or Adverse Reaction to Drug. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Depression is a common mental disorder in patients undergoing maintenance hemodialysis (MHD), which increases the risk of cardiovascular events, hospitalization rates, and mortality, but has not received enough attention from patients and medical staff. Sertraline is a selective serotonin reuptake inhibitor with fewer adverse reactions and higher safety compared to other antidepressants. This study aims to investigate the efficacy and safety of sertraline in patients undergoing MHD with depression. This study used a randomized controlled design and evaluated the depression status of the patients using the Hamilton Depression Scale (HAMD). MHD patients with comorbid depression were recruited and divided into the treatment group and the control group. The treatment group received sertraline for antidepressant therapy, while the control group did not receive any antidepressant medication. To investigate the efficacy and safety of sertraline before and after intervention.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and efficacy of sertraline in depression among adults undergoing dialysis: a systematic review and meta-analysis.
Qammar A, Azeem B, Kumar S, Kumari M, et al · · 2024 · cited 3× · PMID 39649878 · DOI 10.1097/ms9.0000000000002677

Verify or expand the search:

Other trials of Sertraline

Trials testing the same drug.

NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT06827431 — The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression · Phase 3 · not yet recruiting
NCT05973786 — The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in · Phase 3 · recruiting
NCT05892744 — Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression · Phase 4 · recruiting

Other recruiting trials for Efficacy, Team

Currently open trials in the same condition.

NCT06693440 — The Immune Assessment of PD-1 Antibody Therapy in Tumor · recruiting

Other First Affiliated Hospital of Chongqing Medical University trials

Trials by the same sponsor.

NCT07369713 — Efficacy and Safety of Accelerated Intermittent Theta-burst Stimulation (a-iTBS) in Adolescents With Depressive Disorder · NA · not yet recruiting
NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
NCT07409870 — An Integrated Multi-omics Study on the Molecular Mechanisms of Ureteral Stricture · not yet recruiting
NCT07324473 — Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired R · Phase 2 · not yet recruiting
NCT07203144 — Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06124417 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Chongqing Medical University
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06124417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing